Your browser doesn't support javascript.
loading
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
Murray, Thomas S; Stanley, Gail; Koff, Jonathan L.
Afiliación
  • Murray TS; Department of Pediatrics, Section Infectious Diseases and Global Health, Yale University School of Medicine, PO Box 208064, 333 Cedar Street, New Haven, CT 06520-8064, USA. Electronic address: Thomas.s.murray@yale.edu.
  • Stanley G; Department of Internal Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street TAC-441 South, New Haven, CT 06520-8057, USA; Adult Cystic Fibrosis Program; Yale University Center for Phage Biology & Therapy. Electronic address: gail.stanley@yale.edu.
  • Koff JL; Adult Cystic Fibrosis Program; Yale University Center for Phage Biology & Therapy; Department of Internal Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street TAC-455A South, New Haven, CT 06520-8057, USA. Electronic address: jon.koff@yale.edu.
Infect Dis Clin North Am ; 38(1): 149-162, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38280761
ABSTRACT
Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Stenotrophomonas maltophilia / Fibrosis Quística / Staphylococcus aureus Resistente a Meticilina / Antiinfecciosos Límite: Humans Idioma: En Revista: Infect Dis Clin North Am Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Stenotrophomonas maltophilia / Fibrosis Quística / Staphylococcus aureus Resistente a Meticilina / Antiinfecciosos Límite: Humans Idioma: En Revista: Infect Dis Clin North Am Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos